These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22277284)

  • 1. A test of independence of discounting from quality of life.
    Attema AE; Brouwer WB
    J Health Econ; 2012 Jan; 31(1):22-34. PubMed ID: 22277284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences.
    Stalmeier PF; Lamers LM; Busschbach JJ; Krabbe PF
    Med Care; 2007 Sep; 45(9):835-41. PubMed ID: 17712253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead time TTO: leading to better health state valuations?
    Attema AE; Versteegh MM; Oppe M; Brouwer WB; Stolk EA
    Health Econ; 2013 Apr; 22(4):376-92. PubMed ID: 22396243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new and more robust test of QALYs.
    Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
    J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospect theory in the health domain: a quantitative assessment.
    Attema AE; Brouwer WB; I'Haridon O
    J Health Econ; 2013 Dec; 32(6):1057-65. PubMed ID: 24103499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gap effect: discontinuities of preferences around dead.
    Stalmeier PF; Busschbach JJ; Lamers LM; Krabbe PF
    Health Econ; 2005 Jul; 14(7):679-85. PubMed ID: 15744750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tests of QALYs when health varies over time.
    Bleichrodt H; Filko M
    J Health Econ; 2008 Sep; 27(5):1237-49. PubMed ID: 18644640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double discounting of QALYs.
    MacKeigan LD; Gafni A; O'Brien BJ
    Health Econ; 2003 Feb; 12(2):165-9. PubMed ID: 12563665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
    Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a discrete choice experiment to estimate health state utility values.
    Bansback N; Brazier J; Tsuchiya A; Anis A
    J Health Econ; 2012 Jan; 31(1):306-18. PubMed ID: 22197308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of an economic model of health states worse than dead.
    Sharma R; Stano M
    J Health Econ; 2010 Jul; 29(4):536-40. PubMed ID: 20633775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A linear index for predicting joint health-states utilities from single health-states utilities.
    Basu A; Dale W; Elstein A; Meltzer D
    Health Econ; 2009 Apr; 18(4):403-19. PubMed ID: 18773392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.